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Gram-negative sepsis is a frequent complication in patients
with acute renal failure. This study tested whether acute
tubular injury, for example, induced by cisplatin (CP) or
urinary tract obstruction, enhances renal cytokine responses
to endotoxin (lipopolysaccharide (LPS)), potentially
contributing to tissue damage. CD-1 mice were subjected to
CP or vehicle injection. After 24 or 72 h, LPS or its vehicle was
given. At 2 h post LPS or vehicle administration, plasma/renal
cortical tumor necrosis factor (TNF)-a, monocyte
chemoattractant protein-1 (MCP-1), and interleukin-10, and
their corresponding renal cortical mRNAs were assessed
(representing pro-anti-inflammatory cytokines, and a
chemokine, respectively). Comparable studies were
conducted in mice 24 h post unilateral ureteral obstruction
(UUO). Cultured human proximal tubular (HK-2) cell TNF-a
responses to CP7LPS were also assessed. CP alone caused
either minimal or no increases in cytokine levels. However, CP
dramatically augmented cytokine responses to LPS (up to
5–10 vs LPS alone). The cytokine increases were
paralleled by changes in their mRNAs. UUO also sensitized
to LPS. CP alone did not alter HK-2 cell TNF-a/mRNA.
However, CP ‘primed’ the cells to LPS (B50–100%
greater TNF-a/mRNA increases vs LPS alone). CPþ LPS
also caused synergistic cell death (lactate dehydrogenase
release). We conclude that (1) diverse forms of tubular
injury can sensitize the kidney to LPS, increasing
cytokine production; (2) proximal tubules are involved;
(3) LPS ‘priming’ has broad-based consequences,
impacting diverse pro- and anti-inflammatory pathways;
and (4) increased transcriptional events may be at least
partially involved.
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Within 18–24 h of sustaining ischemic, toxic, or physical
damage (e.g., ureteral obstruction), the kidney becomes
relatively resistant to superimposed injurious events.1–15 The
pathophysiological basis for this phenomenon, denoted by
the term ‘acquired cytoresistance’, is incompletely under-
stood. However, it likely involves upregulation of selected
stress proteins (e.g., heme oxygenase-1, ferritin, heat shock
proteins5–13), and an increase in the plasma membrane
cholesterol content.14–16 These adaptive changes presumably
act in concert to guard the kidney from further potential
damage (e.g., nephrotoxic/ischemic injury) during the
recovery phase of acute renal failure (ARF).
Despite a remarkable capacity for renal repair, mortality rates
in patients with ARF remain high, ranging from B25 to
75%.17–21 Indeed, recent clinical evidence suggests that even
mild acute renal injury, insufficient to require dialytic interven-
tion, can decrease patient survival rates.19,20 Multivariate
analyses indicate that this linkage is not simply due to increased
comorbid events in ARF patients. Rather, renal injury, per se,
may adversely impact patient outcomes. These considerations
suggest a seeming paradox: although the acutely injured kidney
may acquire ‘cytoresistance’, a correlate of this state might be a
predilection to extra-renal tissue damage (conceptually remi-
niscent of Bricker’s ‘renal trade-off’ hypothesis22).
A recent study from this laboratory23 suggested one
potential mechanism by which an acutely damaged kidney
might predispose to extra-renal tissue damage: When mice
were challenged with endotoxemia (lipopolysaccharide
(LPS)) during either the induction or the maintenance phase
of ischemic ARF, an approximate doubling of tumor necrosis
factor (TNF)-a generation resulted, compared to LPS-treated
controls. Parallel results were obtained in vitro: when
cultured renal human proximal tubular (HK-2) cells were
subjected to mitochondrial blockade (antimycin A), the
cells mounted exaggerated TNF-a/TNF-a messenger ribo-
nucleic acid (mRNA) responses to LPS. TNF-a is a well-
known mediator of multi-organ tissue damage. Thus, if the
injured kidney were to become hyper-responsive to LPS,
increasing circulating TNF-a levels, an exacerbation of
tissue injury and a worsening of patient outcomes could
conceivably result.
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Given the potential clinical relevance of these experi-
mental observations, the present study was undertaken to
address two important, and related, questions: First, is the
phenomenon of exaggerated TNF-a generation during
endotoxemia unique to the post-ischemic kidney, or can this
phenomenon be induced by more diverse forms of acute
renal damage? Second, is this hyper-responsive state re-
stricted to TNF-a expression, or might other cytokines and/
or chemokines also be involved? Experiments designed to
address these issues form the basis of this report.
RESULTS
Renal cortical mRNA changes in response to cisplatin,
LPS, and CPþ LPS
Effects of cisplatin on non-LPS-treated mice. Cisplatin (CP)
caused mild TNF-a, monocyte chemoattractant protein
(MCP-1), and interleukin (IL)-10 mRNA increases at one
or both of the selected time points: at 24 h, TNF-a, and MCP-1,
but not IL-10, mRNA were increased; at 72 h, elevations were
observed in all the three mRNAs (Figures 1 and 2).
Effects of LPS on non-CP-treated mice. LPS dramatically
increased all three mRNAs at both time points, compared to
saline-injected controls (Pp0.001 for each; P-values not
depicted in Figures 1 and 2 for simplicity).
Effects of LPS on CP-treated mice. CP-pretreated mice
mounted greater TNF-a and MCP-1 mRNA responses to LPS
than did saline-pretreated controls. This was true at both the
24- and 72-h time points (Figures 1 and 2). CP treatment
also caused greater IL-10 mRNA responses to LPS (vs LPS-
injected controls); however, this was true only at the 72 (not
24 h) time point.
Plasma cytokine levels in CP experiments
Independent CP effects on TNF-a. Plasma TNF-a was
undetectable in control samples and in samples obtained at
24 h post CP treatment (Table 1a). However, by 72 h post CP
injection, a very small, but significant, increase in plasma
TNF-a levels was observed (rising from 0 to 1977 pg/ml;
Table 1b). The degree of plasma TNF-a elevations strongly
correlated with the degree of renal failure, as denoted by
corresponding blood urea nitrogen (BUN) levels (range of
BUNs 54–201 mg/dl; r¼ 0.93 vs corresponding TNF-a levels;
Po0.001). BUNs for the CP-treated groups at 24 and 72 h
were 53712 and 103723 mg/dl, respectively (Table 1a and b).
Independent CP effects on MCP-1. MCP-1 was detected in
all control plasma samples, and rose with CP treatment
(B2 and 4 higher than control values at 24 and 72 h,
respectively; Table 1a and b).
Independent CP effects on IL-10. IL-10 could not be
detected in control plasma samples, and remained undetect-
able despite CP treatment (Table 1a and b).
LPS effects on plasma cytokines without CP exposure. As
shown in Table 1a and b, LPS, by itself, induced marked
increases in all three plasma cytokine levels (compare LPS
alone vs saline treatment alone).
Impact of prior CP treatment on LPS-induced changes
in plasma cytokine levels. When LPS was injected into
CP-treated mice, B5–10-fold greater increases in TNF-a
and IL-10 levels were induced, compared to their saline-
matched/LPS-injected controls. This was true at both the
24- and 72-h time points (Table 1a and b). CP pretreatment
also sensitized to LPS-mediated plasma MCP-1 increases, but
to a much lesser extent than the changes that were observed
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Figure 1 | Renal cortical cytokine mRNAs: 24 h post CP
injection7LPS. Four groups of mice are depicted: mice that were
subjected to i.p. injection of either saline (S) or CP, and then, 24 h
later, received either i.v. LPS or i.v. saline (i.e., ‘no LPS’). Cytokine
RT-PCR products were expressed as ratios to the GAPDH product.
Statistical comparisons are between the values in the S vs CP (no LPS
treatment), or S vs CP (each with LPS treatment). CP, by itself, caused
modest increases in TNF-a mRNA and MCP-1 mRNA, but not in IL-10
mRNA. LPS alone increased all three mRNAs (vs saline alone; Po0.01
in all instances; not depicted). LPS injection into CP-treated mice
produced statistically greater increases in TNF-a mRNA and MCP-1
mRNA, vs LPS injection into saline-treated controls.
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Figure 2 | Renal cortical mRNAs: 72 h post CP injection7LPS. The
experimental groups are the same as depicted in Figure 1 (except the
timing of the experiments). By 72 h, CP treatment had increased all three
mRNAs, compared to saline (S)-treated controls. LPS alone also increased
all three mRNAs (vs saline controls, Po0.01 in all instances; not
depicted). LPS injection induced significantly greater increases in all
three mRNAs in CP-pretreated mice, vs in their saline-pretreated controls.
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in TNF-a and IL-10. Relative differences in cytokine
responses to LPS in CP vs non-CP-treated mice are shown
in Figure 3.
Renal cortical cytokine levels in CP experiments
Effects of CP in the absence of LPS. No significant changes
in renal cortical TNF-a or IL-10 levels were seen at 24 or 72 h
post CP treatment (vs values obtained from saline-injected
controls). However, CP slightly increased renal cortical MCP-1
values at both time points (Table 2a and b).
Effects of LPS in the absence of CP. In contrast to CP, LPS
induced marked increases in all three cytokines in the renal
cortex (Table 2a and b; compare LPS vs saline values).
Effects of CP pretreatment on LPS-induced changes in renal
cortical cytokine levels. LPS induced greater renal cortical
TNF-a increases in 24 and 72 h post CP-treated mice, than it
did in saline-pretreated controls (Table 2). A preferential
LPS-induced MCP-1 increase was also observed in CP-
pretreated mice, but only at the 24-h time point. CP
pretreatment had no effect on LPS-induced IL-10 responses
(Figure 4).
Extra-renal responses to CP pretreatment, followed by
LPS injection
mRNAs. CP-treated mice, challenged at 24 h with LPS,
showed no preferential increase in TNF-a mRNA within the
small intestine, lung, or spleen (vs control, LPS-challenged
mice; Figure 5). However, a 2 increase in hepatic TNF-a
mRNA was observed (vs LPS-treated controls).
Hepatic TNF-a levels. CP-treated mice receiving LPS
developed significantly higher hepatic TNF-a cytokine
levels than did control, LPS-challenged mice (CPþ LPS, 987
13 pg/mg; LPS alone, 5975 pg/mg protein; Po0.02). This
difference was due to exaggerated LPS responsiveness, not
due to a direct CP effect: this is because CP alone did not
raise hepatic TNF-a levels (CP/no LPS, 2471 pg/mg;
controls/no LPS, 2772 pg/mg protein).
Unilateral ureteral obstruction experiments: renal mRNA
assessments
Obstruction alone. As shown in Figure 6, 24 h of unilateral
ureteral obstruction (UUO) significantly increased MCP-1
mRNA, but not TNF-a mRNA or IL-10 mRNA (vs
nonobstructed controls).
LPS effects on nonobstructed kidneys. LPS increased all
three mRNA levels vs saline-injected controls (Figure 6; each
Po0.01).
LPS effects on obstructed kidneys. LPS caused significantly
greater increases in all three cytokine mRNAs in the
obstructed kidneys, vs those in the nonobstructed controls
(B3 for both TNF-a and IL-10; B33% increase for
MCP-1; Figure 6).
Table 1 | Plasma cytokine levels in control mice and CP-treated mice without or with superimposed LPS treatment
Saline CP LPS CP+LPS
(a) 24-h plasma cytokine results
TNF-a (pg/ml) 0.00 070 (NS) 514743* 30827712 (o0.001)
MCP-1 (ng/ml) 0.2570.06 0.5270.09 (0.03) 8773* 11475 (o0.005)
IL-10 (pg/ml) 070 070 (NS) 6977172* 695171119 (o0.001)
BUN (mg/dl) 2572 53712 (o0.05) 3171* 3874 (o0.025)
(b) 72-h plasma cytokine results
TNF-a (pg/ml) 070 1977 (o0.05) 11727254* 76737828 (o0.001)
MCP-1 (ng/ml) 0.1570.03 0.6470.11 (o0.001) 137727* 159713 (o0.04)
IL-10 (pg/ml) 070 070 9907184* 56117906 (o0.005)
BUN (mg/dl) 2572 103723 (o0/15) 3071* 120720 (o0.005)
BUN, blood urea nitrogen; CP, cisplatin; IL-10, interleukin-10; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; NS, not significant; TNF-a, tumor necrosis factor-a.
The numbers in parentheses represent P-values derived by comparing plasma values from CP-treated mice vs control (saline injected) mice, or LPS-treated mice vs CP+LPS-treated
mice. All plasma values obtained from LPS-treated mice were statistically greater (*Po0.01) than the values observed in control plasma. BUNs obtained in terminal plasma samples
are presented. Graphic comparisons of the LPS7CP results are presented in Figure 3. Note: TNF-a and IL-10 results are given as pg/ml, whereas MCP-1 results are given as ng/ml.
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Figure 3 | Relative % increases in plasma cytokine levels
following LPS injection in CP-pretreated vs non-CP-treated mice.
The individual values used to calculate these changes are presented
in Table 1a and b. This figure is used to contrast the relatively greater
LPS-induced plasma cytokine increases observed in CP- vs non-CP-
treated mice. At 24 h post CP treatment, LPS induced B5–10-fold
greater increases in plasma TNF-a and IL-10, compared to LPS
injection into saline-pretreated controls. Marked TNF-a and IL-10
hyper-responsiveness to LPS was also observed in the 72 h post
CP-treated mice vs control mice subjected to LPS injection. Although
LPS injection into CP-treated mice induced statistically greater
increases in plasma MCP-1 than LPS injection into control mice, these
differences were far less dramatic than the plasma TNF-a and IL-10
results. (Numbers given over each bar equal the P-value comparison
of responses to LPS in CP- vs non-CP-treated mice.)
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UUO experiments: plasma cytokine assessments
Obstruction alone. Neither TNF-a nor IL-10 was detect-
able in plasma obtained from control mice or UUO mice.
MCP-1 was detected in all plasma samples. UUO did not
increase their levels (0.3370.01 vs 0.3170.03 ng/ml: control
vs UUO mice, respectively).
Obstructionþ LPS. LPS injection raised the plasma levels of
all three cytokines. The degree of LPS-induced TNF-a elevations
was greater in UUO mice vs sham-operated controls (694771
vs 428755 pg/ml, respectively; Po0.01). The LPS-induced
MCP-1 increases were also greater in the obstructed vs sham-
operated mice (10577 vs 7874 ng/ml, respectively; Po0.015).
The LPS-induced IL-10 increases were highly variable, and not
statistically greater in UUO mice (6107259 pg/ml) vs sham-
operated controls (5317226 pg/ml).
HK-2 cell experiments
TNF-a cytokine/mRNA levels. LPS exposure approximately
doubled TNF-a mRNA and TNF-a cytokine levels (each
Po0.01 vs values after (C) incubation). CP alone did not
raise TNF-a or TNF-a mRNA. However, CP ‘primed’ the cells
for heightened LPS responses (Figure 7).
Effect of LPS on CP toxicity. Neither CP nor LPS induced
overt cytotoxicity, as assessed by % LDH release (671, 871,
and 771%; controls, LPS, and CP treatment, respectively).
However, CPþ LPS caused synergistic toxicity (1571% LDH
release; Po0.001 vs LPS or CP alone).
DISCUSSION
The present study provides substantial support for our
previously advanced hypothesis:23 that pre-existent acute
renal injury, insufficient by itself to increase circulating
cytokine levels, can ‘prime’ the kidney for exaggerated
cytokine responses to LPS. Gram-negative sepsis is a frequent
complication, and a leading cause of death, in patients with
ARF. Thus, the observation that acute renal injury can
augment LPS-triggered cytokine generation could have
potential clinical relevance.
Table 2 | Renal cortical cytokine levels in control mice and CP-treated mice without or with LPS injection (BUN concentrations
as per Table 1)
Saline CP LPS CP+LPS
(a) 24-h renal cortical cytokine results
TNF-a (pg/mg) 4873 5476 (NS) 7175* 8476 (o0.001)
MCP-1 (pg/mg) 1371 2071 (o0.001) 806742* 14027139 (o0.005)
IL-10 (pg/mg) 9775 9575 (NS) 13078* 149715 (NS)
(b) 72-h renal cortical cytokine results
TNF-a (pg/mg) 5075 5276 (NS) 7476* 161731 (o0.005)
MCP-1 (pg/mg) 1472 4174 (o0.005) 10257143* 11037208 (NS)
IL-10 (pg/mg) 102710 74711 (NS) 132713* 139713 (NS)
CP, cisplatin; IL-10, interleukin-10; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; NS, not significant; TNF-a, tumor necrosis factor-a.
The numbers in parentheses represent P-values derived by comparing CP vs control (saline) values, or LPS vs CP+LPS values. All values obtained following LPS alone were
statistically different from control values (*Po0.01 vs saline). All values are given as pg/mg tissue protein extract. Graphic comparisons of LPS vs LPS+CP results are given in Figure 4.
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Figure 4 | Relative % increases in renal cortical cytokine levels:
LPS effects on CP-pretreated vs control mice. The individual values
used to calculate these changes are presented in Table 2a and b. The
figure contrasts the relative LPS-induced increases in renal cortical
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Figure 5 | LPS effects on hepatic, splenic, intestinal, and
pulmonary TNF-a mRNA in CP-pretreated and control mice. When
challenged with LPS at 24 h post CP treatment, only the liver showed
a preferential increase (B2 ) in TNF-a mRNA, compared to control
mice challenged with LPS. The degree of preferential increase (B2 )
was comparable to that which had been observed in the kidney (see
Figure 1). Thus, these results suggest that the liver as well as the
kidney may have contributed to exaggerated TNF-a generation in
CP-pretreated mice in response to LPS.
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In our prior study, we demonstrated heightened LPS-
driven TNF-a production in the setting of post-ischemic
renal damage.23 However, it was not determined whether this
phenomenon is unique to the post-ischemic kidney, or
whether alternative forms of renal injury might elicit the
same response. To address this issue, we have now measured
TNF-a levels in both plasma and kidney in a nephrotoxic
model of renal injury: CP-induced ARF. Assessments were
made at two time points, 24 and 72 h post CP administration,
to ascertain the durability of this phenomenon. As progres-
sive azotemia develops over this 3-day period (BUNs rising
from 50 to 150 mg/dl), the possible impact of uremia on LPS-
mediated cytokine expression could also be assessed. The
results obtained indicate that CP can, like renal ischemia,
‘prime’ the mouse to an exaggerated LPS response. This is
denoted by the finding that CP-pretreated mice hadB5-fold
greater LPS-induced plasma TNF-a increases than LPS-
challenged controls. That essentially identical LPS-induced
TNF-a increments were observed at 24 and 72 h post CP
injection indicates that progressive uremia did not alter this
response. It is noteworthy that LPS also induced greater renal
cortical TNF-a increases in CP-pretreated mice vs their
matched controls. While this does not prove that the kidney
was the source, or even the major contributor to, the
increased plasma TNF-a levels, it is at least consistent with
this hypothesis. (This issue will be addressed in greater detail
below.)
In our previous study of post-ischemic renal injury,23
increased sensitivity to LPS was assessed only by measuring
TNF-a levels. To ascertain whether renal injury might
predispose to more generalized cytokine induction, MCP-1
and IL-10, as well as TNF-a, were measured in the present set
of experiments. TNF-a, IL-10, and MCP-1 were selected
because they represent a proinflammatory cytokine, an anti-
inflammatory cytokine, and a chemokine, respectively.24–26
Thus, hyper-responsiveness of all the three during LPS
exposure would imply a relatively broad-based cytokine-
induction state. The results obtained indicate that CP can,
indeed, evince this response, as indicated by the following
pieces of information: (i) when the 24-h and/or 72-h CP-
treated mice were challenged with LPS, B5–10-fold greater
plasma IL-10 and TNF-a increases were observed, compared
to LPS-matched controls, and (ii) CP pretreatment approxi-
mately doubled intra-renal MCP-1 and TNF-a accumulation
in response to LPS. In composite, these findings extend our
previous observations23 in two important ways: first, they
indicate that exaggerated TNF-a responsiveness to LPS
injection is not restricted to the post-ischemic kidney (given
the current CP results), and second, that multiple cytokines
(and not just TNF-a) participate in this phenomenon.
In the aftermath of both ischemic- and CP-induced renal
injury, substantial intra-renal inflammation results.27–30 This
raises the possibility that intra-renal lymphocyte and
macrophage infiltrates, rather than resident renal cells, could
have been the source of the exaggerated LPS-initiated
cytokine response. In an effort to exclude this possibility,
pure cultures of proximal tubular (HK-2) cells were exposed
to CP7LPS. CP alone failed to increase either TNF-a or its
mRNA. However, when CP-exposed cells were coincubated
with LPS, 50–100% increases in TNF-a mRNA/TNF-a
cytokine levels resulted (vs LPS treatment alone). Thus,
these cell culture data recapitulate the afore-noted in vivo
results: CP, in a regimen which did not independently incite
TNF-a production, ‘primed’ tubular cells to an exaggerated
LPS response. This strongly suggests that injured renal
tubular cells, per se, and in the absence of infiltrating
inflammatory cells, likely contributed to the observed in vivo
renal cortical results.
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Figure 7 | HK-2 cell TNF-a mRNA (left panel) and TNF-a cytokine
levels (right panel) in response to CP exposure7LPS. LPS caused
a significant increase in both TNF-a and its mRNA (Po0.01 in each
instance vs control (C) incubated cells). CP, on its own, did not
change either TNF-a or TNF-a mRNA. Nevertheless, CP sensitized to
LPS, raising both TNF-a mRNA and TNF-a cytokine levels byB50 and
B100%, respectively (compared to LPS treatment alone).
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In a further attempt to dissociate renal inflammatory
infiltrates from heightened sensitivity to LPS, mice were
subjected to acute ureteral obstruction and then challenged
with LPS. The 24-h ureteral obstruction model was selected
for this purpose because, unlike CP and ischemia, it is
insufficient in duration to evoke obvious interstitial inflam-
matory cell infiltrates.31 Nevertheless, short-term obstruction
was sensitized to LPS-driven cytokine generation, as assessed
by intra-renal cytokine mRNA expression and corresponding
circulating cytokine levels. This furthers supports the concept
that renal injury, per se, independent of inflammatory cell
infiltration, is sufficient to evoke cytokine hyper-responsive-
ness to LPS. In further contrast to ischemia–reperfusion and
CP-induced ARF, 24 h of UUO does not induce significant
azotemia or overt tubular cell death. Thus, even modest renal
parenchymal damage, and in the absence of renal failure, is
sufficient to trigger the LPS-‘sensitization’ effect.
In our previous studies of ischemic ARF, heightened TNF-a
generation during LPS exposure occurred despite the fact
that ischemia alone did not raise intra-renal or plasma TNF-a
levels.23 This indicated that renal injury had ‘primed’ the
kidney for an exaggerated LPS–TNF-a response. The present
experiments demonstrate this same phenomenon. As shown
in Tables 1 and 2, CP had either no effect or quantitatively
small effects on plasma or renal cytokine levels in the absence
of LPS. However, in the presence of LPS, the cytokine
increases observed in the CP-treated mice exceeded the sum
of independent LPSþCP effects. This same principle was
supported by the results of the UUO and HK-2 cell
experiments. Of potential mechanistic interest, the cytokine
increases were, in general, paralleled by changes in their
mRNAs. While it is not possible to draw firm mechanistic
conclusions, this suggests that the injury-induced ‘priming’
to LPS–cytokine responses may have stemmed, at least in
part, from increased transcriptional events.
Ureteral obstruction and post-ischemic ARF are ‘renal-
specific’ forms of injury. Thus, it seems reasonable to
hypothesize that, in these disease models, the injured kidney
was the dominant site of excess cytokine generation during
exposure to LPS. However, in the case of CP administration,
systemic/extra-renal toxicity can result. This raises the
distinct possibility that extra-renal injury could have
sensitized the involved tissues to LPS, priming them for
excess cytokine production. To pursue this possibility, CP-
treated and control mice were injected with LPS, and extra-
renal TNF-a mRNA (chosen as a surrogate marker for tissue
cytokine production) was assessed. The gut and hemato-
poietic tissues are prime extra-renal targets of acute CP
toxicity. Nevertheless, CP pretreatment did not augment gut
or splenic TNF-a mRNA expression in response to LPS. The
same was true for the lung. Conversely, CP pretreatment
approximately doubled hepatic TNF-a mRNA and TNF-a
cytokine responses to LPS. The reason why the liver (but not
other test organs) responded like the kidney remains
unknown. However, it is noteworthy that the liver ranks
second to the kidney in terms of CP tissue uptake. This
suggests that CP tissue accumulation plays a central role.
That parallel renal and hepatic responses to CPþ LPS were
observed in these experiments implies that the current
observations could have broad-based biologic relevance,
rather than reflecting a renal specific phenomenon.
In conclusion, the present study extends our previous
observations23 of renal ischemia-induced ‘priming’ to LPS-
mediated cytokine generation in a number of important
ways: (1) pleomorphic forms of renal injury appear capable
of initiating this state, as indicated by the current CP and
ureteral obstruction experiments; (2) ‘downstream’ expres-
sion of this hyper-responsiveness is also pleomorphic, given
that a proinflammatory (TNF-a), an anti-inflammatory (IL-
10) cytokine, and a chemokine (MCP-1) can participate; (3)
this phenomenon arises, at least in part, from damaged
proximal tubular cells, based on the current HK-2 cell results;
(4) that mRNA levels parallel their respective cytokine levels
suggests that transcriptional events are partially involved; and
(5) injury-induced hyper-responsiveness to LPS is not a
kidney-specific phenomenon, based on the current hepatic
results. The impact of injury-induced hyper-responsiveness
to LPS, both on the ARF kidney and on extra-renal organs,
remains unknown at this time. However, the data suggest a
seeming paradox: although the post-injured kidney may
acquire ‘cytoresistance’, that same cytoresistant kidney may
also contribute to extra-renal damage by ‘priming’ it for
enhanced LPS-mediated cytokine and chemokine produc-
tion. If true, this could help to explain why ARF might
worsen clinical outcomes independent of the adverse
consequences of filtration failure.
MATERIALS AND METHODS
CP model of ARF
Male CD-1 mice (25–35 g; from Charles River Laboratories,
Wilmington, MA, USA), maintained under routine vivarium
conditions, were used for all in vivo experiments. CP (Sigma
Chemicals, St. Louis, MO, USA) was administered at a concentra-
tion of 30 mg/kg by intraperitoneal (i.p.) injection (stock solution of
1 mg/ml in normal saline). Control mice received an equal volume
of normal saline.
Experiments performed during the induction phase (24 h)
of CP-induced ARF
In all, 16 mice received i.p. injections of CP, as noted above. Also, 16
mice, receiving an equal volume of saline, served as controls. At 24 h
post injection, control-, and CP-treated mice were divided into two
subgroups (saline injection vs LPS injection). They were placed into
restraining tubes and injected via the tail vein with either Escherichia
coli LPS (2 mg/kg; 0111:B4; L-2630; Sigma Chemicals; in B80ml
saline) or an equal volume of saline. This created four groups:
1. i.p. saline, followed 24 h later by intravenous (i.v.) saline (n¼ 8);
2. i.p. saline, followed 24 h later by i.v. LPS (n¼ 8);
3. i.p. CP, followed 24 h later by i.v. saline (n¼ 8);
4. i.p. CP, followed 24 h later by i.v. LPS (n¼ 8).
At 2 h post tail vein injections, each mouse was deeply anesthetized
(3–4 mg i.p. pentobarbital). The abdominal cavity was opened, and a
plasma sample was withdrawn from the inferior vena cava. Both
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kidneys were resected, iced, and the cortices dissected. Protein and
RNA were extracted.32,33 Plasma and renal protein extracts were
assayed for TNF-a, MCP-1, and IL-10 by enzyme-linked immuno-
sorbant assay (ELISA) (TNF-a, IL-10: R & D Systems; Minneapolis,
MN, USA; MCP-1 BD Biosciences, San Diego, CA, USA).33,31 RNA
samples were used for semiquantitation of TNF-a, MCP-1, and IL-10
mRNAs by reverse transcriptase-polymerase chain reaction (RT-PCR).
TNF-a and MCP-1 mRNAs were assayed as noted previously.32,33 IL-
10 mRNA was assessed with the same general methodologies, using the
following conditions (annealing temperature 58.51C 34 cycles) and
primers (resulting product, 520 bp in length):
50-TGCACTACCAAAGCCACAAAGCAG-30;
50-TGGCCTTGTAGACACCTTGGTCTT-30.
The results obtained from the above experiments were used to (1)
assess the independent effects of either CP or LPS injection on each
plasma and renal cortical end point and (2) ascertain whether CP
pretreatment alters LPS responsiveness. BUNs gauged the severity of
renal injury.
Experiments performed during the maintenance phase (72 h)
of CP-induced ARF
The experiments described immediately above were repeated in their
entirety, with the exception that they were performed at 72 h post
CP or saline injection in order to gauge the durability of the above
gathered information.
Effect of CP on extra-renal cytokine expression
As CP can induce extra-renal damage, its possible impact on nonrenal
cytokine responsiveness to LPS was assessed. Six mice were injected
with CP, followed 24 h later by i.v. LPS. At 2 h post LPS, they were
anesthetized and samples of the following tissues were resected and
extracted for RNA: upper small intestine, spleen, lung, and liver.33
The samples were assayed for TNF-a mRNA (as a representative
cytokine response in these tissue samples). The results were contrasted
with those obtained from six control mice injected with LPS.
Only the liver had an abnormal TNF-a mRNA response to
LPS (see Results). To ascertain whether there was an associated
increase in hepatic TNF-a cytokine, the above experiment was
repeated, the liver was extracted 2 h post LPS injection, and
TNF-a levels were assessed. To ascertain the possible CP effects
on hepatic TNF-a, independent of LPS, three CP and three control
mice had their livers extracted 24 h post CP or saline injection for
TNF-a cytokine assay.
UUO experiments
The following experiment assessed whether an acute form of
renal injury that was not associated with extra-renal tissue damage,
and which does not induce tubular necrosis, alters cytokine
responsiveness to LPS. In all, 12 mice underwent a midline
laparotomy. The left ureter of each was ligated with a silk suture
1 cm below its renal origin.31 The right kidney was left undisturbed.
The abdominal incisions were sutured and the mice were allowed
to recover. A total of 12 mice underwent sham surgery. At 24 h
post surgery, half of the mice in each group received i.v. LPS or
vehicle. After 2 h, the mice were re-anesthetized, a heparinized
blood sample was withdrawn from the inferior vena cava, and
the kidneys were resected. Plasma samples were assayed for TNF-a,
MCP-1, and IL-10. Cortical RNA samples were assayed for TNF-a,
MCP-1, IL-10, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNAs.
HK-2 cell experiments
CP and LPS can alter renal hemodynamics, and potentially incite
intra-renal inflammatory cell infiltrates. Thus, these in vitro
experiments assessed direct proximal tubular cell responses to CP/
LPS (i.e., in the absence of these systemic factors). HK-2 cells,
cultured in keratinocyte serum-free medium (K-SFM) in T75 Costar
flasks,34 were used for this purpose. They were seeded into either
fresh T75 flasks, or into 24-well Costar plates. The following
experiments were performed.
Effect of CP-LPS on TNF-a/mRNA responses. T75 flasks of
HK-2 cells (n¼ 32), grown to near confluence over 2–3 days, were
divided into four groups (n¼ 8 for each): (1) control in-
cubation 24 h; (2) control incubation 2 h, followed by LPS
exposure (100 mg/ml 22 h); (3) incubation with 10 mM CP 24 h;
or (4) incubation with CP 2 h, followed by coincubation with
LPS 22 h. After completing the incubations, four flasks per group
underwent RT-PCR analysis for human TNF-a mRNA and GAPDH
mRNA.23 The remaining 16 flasks underwent protein extraction and
human TNF-a analysis (ELISA; 23). (Note: Given limited sample
sizes, TNF-a served as a representative cytokine.) mRNA and
cytokine results were expressed as TNF-a/GAPDH ratios, and as pg/
mg HK-2 cell protein, respectively. Cell injury was gauged by %
lactate dehydrogenase (LDH) release.
Calculations and statistics. All values are presented as
means71 s.e.m. Plasma TNF-a and IL-10 concentrations are given
as pg/ml. Plasma MCP-1 levels are presented as ng/ml (due to the
high levels following LPS treatment). Renal cortical and HK-2 cell
cytokine levels are presented as pg/mg protein. Statistical compar-
isons were carried out by unpaired Student’s t-test. If multiple
comparisons were made, the Bonferroni correction was applied.
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